An anti-CD33 antibody–drug conjugate that targets CD33-positive myeloblasts and delivers the cytotoxic agent calicheamicin to induce DNA double-strand breaks.
Anti-CD33 monoclonal antibody–drug conjugate that binds CD33 on myeloblasts, is internalized, and releases the cytotoxic payload calicheamicin in lysosomes; calicheamicin binds the DNA minor groove and induces double‑strand breaks, leading to apoptosis of CD33-positive cells.
YES
DIRECT
Anti-CD33 antibody-drug conjugate binds CD33, is internalized, and releases calicheamicin that induces DNA double-strand breaks, triggering apoptosis of CD33-positive cells.
An anti-CD33 antibody–drug conjugate that targets CD33-positive myeloblasts and delivers the cytotoxic agent calicheamicin to induce DNA double-strand breaks.
Anti-CD33 monoclonal antibody–drug conjugate that binds CD33 on myeloblasts, is internalized, and releases the cytotoxic payload calicheamicin in lysosomes; calicheamicin binds the DNA minor groove and induces double‑strand breaks, leading to apoptosis of CD33-positive cells.
NO
INDIRECT
Gemtuzumab ozogamicin targets CD33 on cells, is internalized, then releases calicheamicin that binds the DNA minor groove to cause double-strand breaks and apoptosis; DNA is not the targeted antigen.
A BCMA×CD3 bispecific monoclonal antibody immunotherapy (brand: Elrexfio; PF-06863135) that redirects T cells to kill BCMA-expressing myeloma cells.
Elranatamab is a BCMA×CD3 bispecific antibody that binds CD3 on T cells and BCMA on malignant plasma cells, cross-linking them to form an immune synapse and redirect T-cell cytotoxicity and cytokine release to kill BCMA-expressing myeloma cells.
YES
DIRECT
BCMAxCD3 bispecific links T cells to BCMA+ cells, forming an immune synapse and inducing T-cell cytotoxicity (perforin/granzyme apoptosis and cytokine-mediated killing).
A BCMA×CD3 bispecific monoclonal antibody immunotherapy (brand: Elrexfio; PF-06863135) that redirects T cells to kill BCMA-expressing myeloma cells.
Elranatamab is a BCMA×CD3 bispecific antibody that binds CD3 on T cells and BCMA on malignant plasma cells, cross-linking them to form an immune synapse and redirect T-cell cytotoxicity and cytokine release to kill BCMA-expressing myeloma cells.
NO
INDIRECT
Elranatamab binds CD3 on T cells to recruit/activate them and bridge them to BCMA+ myeloma cells; the activated T cells kill the BCMA-expressing tumor cells (via perforin/granzyme), not the CD3+ T cells.
Investigational antibody–drug conjugate administered IV; a tumor-targeting monoclonal antibody is internalized and releases the topoisomerase I inhibitor payload brengitecan, causing DNA damage and tumor cell death.
Tumor-targeting monoclonal antibody binds a surface antigen, is internalized, and releases the camptothecin-derived topoisomerase I inhibitor brengitecan, inducing DNA damage (replication-associated strand breaks) and tumor cell death.
YES
DIRECT
An antibody–drug conjugate binds the tumor-associated surface antigen, is internalized, and releases the topoisomerase I inhibitor brengitecan, causing replication-associated DNA damage and apoptosis of the antigen-expressing cells.